Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.

Jing Liu, Xianglu Sun,Qianyu Du,Jinghao Yao, Mengfen Dai,Qianqian Cheng, Han Xu,Yawei Li, Xiuli Liu,Mingliang Zhang,Yongchun Zhou,Yan Yang

Breast cancer (Dove Medical Press)（2022）

引用 0|浏览2

暂无评分

摘要

Pyrotinib-based regimens showed promising efficacy, with manageable tolerance, and AE occurrence of severe diarrhea and baseline level of serum VEGF-A are helpful in predicting the treatment outcome of pyrotinib in HER2-positive MBC.

查看译文

关键词

HER2,breast cancer,efficacy,prognostic factor,pyrotinib,vascular endothelial growth factor A

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要